Evidence map›Paper›PMID 32540961›Full record

ArticleCancer research2020

HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma.

Yixuan Li, Xiangyang Zhang, Shaoqi Zhu, Eden A Dejene, Weiqun Peng, Antonia Sepulveda, Edward Seto

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 48 citations in OpenAlex.

  1. The histone deacetylase family in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Balkan medical journal · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yixuan LiDepartment of Biochemistry & Molecular Medicine, George Washington Cancer Center, George Washington University School of Medicine & Health Sciences, Washington, D.C.
Xiangyang ZhangDepartment of Neurology, George Washington University School of Medicine & Health Sciences, Washington, D.C.
Shaoqi ZhuDepartment of Physics, Columbian College of Arts & Sciences, George Washington University, Washington, D.C.ORCID 0000-0001-9509-3526
Eden A DejeneDepartment of Biochemistry & Molecular Medicine, George Washington Cancer Center, George Washington University School of Medicine & Health Sciences, Washington, D.C.ORCID 0000-0002-2232-4220
Weiqun PengDepartment of Physics, Columbian College of Arts & Sciences, George Washington University, Washington, D.C.
Antonia SepulvedaDepartment of Pathology, George Washington Cancer Center, George Washington University School of Medicine & Health Sciences, Washington, D.C.
Edward SetoDepartment of Biochemistry & Molecular Medicine, George Washington Cancer Center, George Washington University School of Medicine & Health Sciences, Washington, D.C. seto@gwu.edu.
George Washington University · US

Funding

Tcf/Lef and B-catenin pathway in follicular helper T cellsR01AI121080 · NIAID · UNIVERSITY OF IOWA · PI Hai-Hui Xue · 2016 to 2026
$4.6M
Ezh2 regulates follicular helper T cell differentiationR01AI139874 · NIAID · UNIVERSITY OF IOWA · PI PENG, WEIQUN, XUE, HAI-HUI · 2018 to 2022
$2.4M
Targeting SIRT1 in Mantle Cell LymphomaR01CA187040 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SETO, EDWARD · 2014 to 2018
$1.6M
The Basic and Translational Implication of SIRT1 and DNMT1 in CancerR01CA169210 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SETO, EDWARD · 2012 to 2016
$1.6M
NCI NIH HHS R01 CA169210NCI NIH HHS R01 CA187040NIAID NIH HHS R01 AI121080NIAID NIH HHS R01 AI139874
6 · The paper itself

Abstract

Activation of oncogenic KRAS is the most common driving event in lung adenocarcinoma development. Despite the existing rationale for targeting activated KRAS and its downstream effectors, the failure of clinical trials to date indicates that the mechanism of KRAS-driven malignancy remains poorly understood. Here we report that histone deacetylase 10 (HDAC10) might function as a putative tumor suppressor in mice carrying a spontaneously activated oncogenic

Indexed as

Genes, rasTranscriptional ActivationAdenocarcinoma of LungAnimalsCarcinogenesisCell Line, TumorDisease Models, AnimalGene DeletionGerm-Line MutationHistone DeacetylasesLung NeoplasmsMacrophagesMiceNeoplastic Stem CellsSequence Analysis, RNASOX9 Transcription FactorHistone DeacetylasesSox9 protein, mouseSOX9 Transcription FactorTransforming Growth Factor betaTumor Suppressor Proteins

Identifiers

PMID32540961
PMCPMC7442594
OpenAlexW3034586018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.